Authors
Latest:
Treatment Experience for a Patient With GVHDA patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.
Latest:
Managing AEs Associated With Bispecifics in RRMMClosing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.
Latest:
Primary Focal Therapy for Localized Prostate Cancer: A Review of the LiteratureFocal therapy for prostate cancer could balance undertreatment and overtreatment of localized prostate cancer for highly selected patients. Long-term oncologic outcomes are not yet available for any modality. Patients should be informed regarding currently available outcomes, the necessity of adherence to a stringent follow-up protocol, and the possible need for additional targeted therapy or future radical treatment in case of recurrence.
Latest:
Tagraxofusp in BPDCN: Practical Advice and Future Directions in CareAfter sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.
Latest:
Roger Li, MD, Talks Future Analyses of CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBCRoger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.
Latest:
Medical World News® After Hours: Thoracic Medical Oncologist Inga Lennes, MD, MBA, MPH, on Healthy EatingDuring an After Hours segment of Medical World News®, Inga Lennes, MD, MBA, MPH, spoke about her passion for healthy cooking and how it helps her unwind after a busy week of treating patients.
Latest:
Novel Therapies May Lead to More Treatment Options in Sarcoma SubtypesCAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
Latest:
Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple MyelomaClosing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical ProgressionIn the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Latest:
Martha Ann Raymond, MA, on What Providers Should Do to Enhance Clinical Trial Participation in the COVID-19 EraThe founding executive director of the GI Cancers Alliance discussed important takeaways from a study of patient perspectives of clinical trial participation during the COVID-19 pandemic.
Latest:
Study Impact and Key TakeawaysSagar Lonial, MD, and Ellen Marin, PA-C, discuss the impact and key takeaways from their study as well as study limitations and future directions.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Catherine A. Shu, MD, Reviews Findings of Cohort A of the Phase 1 CHRYSALIS-2 Trial in Pretreated EGFR+ NSCLCCatherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Early Access to Electronic Health Records May Influence the Patient ExperienceIn a recent Hot Topics column, Mehmet Sitki Copur, MD, FACP, et al discussed the pros and cons of patients receiving test results early through electronic medical records.
Latest:
Face-Off: Award Presentations and Event ConclusionJudy concludes the event and presents the awards.
Latest:
Signaling Pathways in the Relapse of GlioblastomaJavier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Clinical Pearls for Community Oncologists Treating Relapsed/Refractory AMLGhayas C. Issa, MD, offers closing thoughts on genetic testing and targeted therapies for patients with relapsed/refractory acute myeloid leukemia.
Latest:
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaThis clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Latest:
Laurie H. Sehn, MD, on the Key Takeaways From the GO29365 Study in DLBCLThe preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.
Latest:
Closing Thoughts on Bispecific Antibodies and the Future of R/R MM TreatmentThe panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.
Latest:
Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial ResultsExamine the efficacy and safety of the BCMA-targeting bispecific antibody elranatamab as monotherapy and in combinations from the Phase 2 MagnetisMM-3 trial in patients with relapsed or refractory multiple myeloma.
Latest:
Nirogacestat Approval Offers Choice to Desmoid Tumor PopulationThe difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
